David Friedland

Author PubWeight™ 10.59^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.	Clin Cancer Res	2007	1.92
2	CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.	J Antimicrob Chemother	2010	1.67
3	CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections.	J Antimicrob Chemother	2010	1.58
4	Phase II study of everolimus (RAD001) in previously treated small cell lung cancer.	Clin Cancer Res	2010	1.20
5	A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.	Clin Cancer Res	2007	0.89
6	A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.	Clin Genitourin Cancer	2006	0.85
7	Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.	Melanoma Res	2007	0.84
8	A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer.	Am J Clin Oncol	2005	0.79
9	Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers.	J Immunol	2006	0.77
10	Association of hearing loss with PHACE syndrome.	Arch Dermatol	2010	0.75